Oncoheroes Biosciences

📢 Exciting News! Our co-founder, Cesare Spadoni, is participating in the EFGCP - European Forum for Good Clinical Practice Better Medicines for Children Conference 2024 in Brussels on Tuesday, October 22! Meet Cesare there as he joins the panel discussing “Paediatric-only Drug Development / First-in-Child Companies.” Representing Oncoheroes Biosciences, a biotech exclusively focused on developing new therapies for childhood cancer, Cesare will address the unique challenges in pediatric drug development and the critical need for innovative solutions to ensure children have access to safe and effective treatments. 🔗 https://lnkd.in/eKrhEpd3

We’re thrilled to announce that Raphaël Rousseau, MD, PhD, is joining Oncoheroes Biosciences' board of directors! Raphaël’s appointment is a significant endorsement from a leading industry expert in the pediatric cancer field. He is a pivotal addition to our team, helping to shape the future of Oncoheroes' mission to develop new therapies for childhood cancer. "I’m excited to join Oncoheroes and help bring new treatments to children with cancer faster. Because they can't wait any longer!" states Raphaël Rousseau. Welcome to the team, Raphaël! We can’t wait to make a difference together. 🎗️ #PediatricOncology #Oncoheroes

Childhood Cancer Awareness Month is in full swing! Oncoheroes Biosciences is proud to once again sponsor CureFest in Washington, DC. As a biotech exclusively focused on developing new therapies for childhood cancer, there’s nowhere else we’d rather be. CureFest is where our community comes together—families, researchers, and advocates—each with a fierce dedication to changing the game for young cancer fighters. We’re honored to stand with them, pushing for real progress that makes a difference. Join CureFest in DC on September 22-24 as we rally for a brighter future for these brave kids. Together, we can make it happen. 🎗️  #OncoheroesBiosciences #CureFest2024 #ChildhoodCancerAwareness #HopeForKids #TogetherForACure

We’re excited to share some incredible news! 🎗️ Oncoheroes Biosciences is the benefactor of the recent BattleCorn Care Packages gala, a foundation created in honor of Jaycee Vallier. 💛 Thanks to the generous grant from this event, we’re now closer to launching the international clinical trial for our lead compound, volasertib, testing its efficacy in five types of pediatric cancer. “Each year we choose a benefactor to receive the efforts of our yearly fundraising in support of research in pediatric cancer. This year we chose Oncoheroes because of their dedication to creating better treatment options for our kids in a space where our government and pharmaceutical industry don’t seem to care. We feel this investment into the future will put our community, our warriors, and our families on a path to better treating and one day eliminate childhood cancers”, explains Curtis Vallier, Chief Operating Officer at BattleCorn Care Packages and Jaycee’s dad. This announcement is especially meaningful as we celebrate Childhood Cancer Awareness Month. We’re grateful for the support of BattleCorn Care Packages, helping us move forward in our mission of finding new therapies for childhood cancer. Together, we’re making strides towards a brighter future for kids battling cancer. Thank you, BattleCorn Care Packages, for your incredible support! 🔗 https://lnkd.in/ekYHFu6J

As we kick off Childhood Cancer Awareness Month, we're thrilled to share a major milestone in our fight against childhood cancer! Oncoheroes Biosciences has secured exclusive worldwide pediatric oncology rights for dovitinib from Novartis. The opportunity to explore this potential option for pediatric cancer treatment marks a significant step forward in our mission to bring new hope to young patients. With clinical trials on the horizon, we’re eager to investigate how dovitinib can make a difference for children facing bone sarcomas and other challenging pediatric cancers. Let’s continue to push boundaries and bring innovative treatments to those who need them most. 🔗 https://lnkd.in/eZJC6DGM #ChildhoodCancerAwarenessMonth #Oncoheroes #PediatricCancer

Brain tumors are the leading cause of cancer-related deaths in children. In the US alone, nearly 4,600 children and teenagers are diagnosed with a brain tumor each year. Despite advancements in medical science, survival rates for certain types of pediatric brain tumors remain stubbornly low, with only around 70% of children surviving five years post-diagnosis. There's an urgent need to improve treatments for kids and teenagers diagnosed with brain tumors. At Oncoheroes Biosciences, we're committed to finding better treatments for children diagnosed with cancer, including brain tumors. This month, we're joining the #GoGrayInMay movement to raise awareness about the harsh reality of pediatric brain tumors as we continue our efforts to initiate an international clinical trial that will assess the efficacy of our lead compound, volasertib, in treating brain cancers like medulloblastoma and DIPG. #BrainTumorAwarenessMonth #BTAM #ChildhoodCancerResearch

📢 Exciting News Alert! We are thrilled to announce that our CEO and Co-Founder, Ricardo Garcia, has been featured in the book "TOP Disruptors - Guide to Entrepreneurs and CEOs Who Stand Out for Their Innovative Talent". This esteemed publication meticulously selects 1,000 Spanish entrepreneurs and CEOs who have demonstrated exceptional leadership and a disruptive approach over the past year. It delves into the profiles of emerging visionaries whose innovative ideas are set to continue revolutionizing industries. We extend our heartfelt thanks to Top Comunicación & RR.PP. for recognizing Ricardo's visionary leadership. ℹ https://lnkd.in/gMyrp5ZG

Nous sommes ravis d'annoncer un partenariat stratégique entre Oncoheroes Biosciences et Elaia Capital SA. Cette collaboration permet à Oncoheroes d'élargir sa présence dans le paysage d'investissement suisse, tandis qu'Elaia Capital ajoute à son portefeuille une entreprise ayant un impact positif et une équipe de professionnels expérimentés et dévoués à sa mission. L'objectif principal est de poursuivre la mission d'Oncoheroes visant à faire progresser de nouvelles thérapies contre le cancer infantile. Contactez-nous pour explorer les opportunités d'investissement et découvrir comment vous pouvez contribuer à cette mission impactante ! We are excited to announce a strategic partnership between Oncoheroes Biosciences and Elaia Capital SA. This collaboration allows Oncoheroes to broaden its presence in Switzerland’s investment landscape, while Elaia Capital adds to its portfolio a company with a positive impact and a team of experienced, mission-driven professionals. The primary goal is to further Oncoheroes’ mission of advancing new therapies for childhood cancer. Contact us to explore investment opportunities and discover how you can contribute to this impactful mission! Ricardo Garcia - Cesare Spadoni - Michael Palma - Teodoro Diaz - Ferran Pérez

🚨 Last chance to be part of our final webinar! Don't miss out on tomorrow's webinar! Hear from Cesare Spadoni and Ricardo Garcia, Oncoheroes Biosciences’ co-founders, as they present an exciting investment opportunity with dual benefits: making a difference and making profits. Date: Tomorrow, Tuesday, April 16th Time: 12 pm EST / 6 pm CET Register now 👇 https://lnkd.in/emybySZn

Exciting News! We're thrilled to announce that Oncoheroes Biosciences, has been selected as one of the eleven finalists for the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit! Scheduled for May 14th–15th, 2024, at the Cleveland Clinic Abu Dhabi, this event aims to cultivate a thriving ecosystem for early-stage entrepreneurs in the life sciences sector. During the event, Cesare Spadoni, Oncoheroes Co-Founder, will present the company's pioneering work to a panel of judges comprising industry leaders and investors, including Laurie Glimcher, President and CEO at the Dana-Farber Cancer Institute, Jorge A. Guzman, MD, MBA, CEO at Cleveland Clinic Abu Dhabi, Shahrukh Hashmi, Director of Research at the Department of Health Abu Dhabi, David Hung, M.D., President and CEO at Nuvation Bio, Yasmine Hayek Kobeissi Ph.D, Executive Director at Blue Horizon Advisors, and Anya Schiess, Managing Partner at J.P. Morgan Life Sciences Private Capital. This recognition underscores Oncoheroes Biosciences' unwavering commitment to advancing novel treatments for childhood cancers. https://lnkd.in/ebxbVCK6